Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Transcode Therapeutics Logo
Transcode Therapeutics Growth Score
92
CB Rank
1874
Heat Score
78
TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.
Founded
obfuscation
PublicPost-IPO Debt Newton, Massachusetts, United States11-50 www.transcodetherapeutics.com
Biotechnology
Health Care
Oncology
Therapeutics
Overview

Transcode Therapeutics
Total Funding
obfuscation
Growth Score
92
Heat Score
78

Total Funding
obfuscation
obfuscation
Post-IPO Debt raised
obfuscation
Growth Score92
-6 pts
in past quarter
Heat Score 78
2 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Transcode Therapeutics

CB Rank
1874
TransCode Therapeutics is an RNA oncology company that develops and commercializes drugs for the treatment of metastatic cancer.
Founded
obfuscation
PublicPost-IPO Debt Newton, Massachusetts, United States11-50 www.transcodetherapeutics.com
Biotechnology
Health Care
Oncology
Therapeutics

Funding Rounds

Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name Transcode Therapeutics, Inc.
Operating Status Active
Stock Symbol  NASDAQ:RNAZ
Company Type For Profit
Founders  Anna Moore, R. Michael Dudley, Zdravka Medarova
About the Company

TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, which they believe has blockbuster potential, targets an RNA molecule that is the driver of metastatic disease across multiple tumor types

and has been validated pre-clinically in its lab at MGH.

Contact Email info@transcodetherapeutics.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Transcode Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

TTX-MC138
A therapeutic candidate designed to inhibit microRNA-10b to treat metastatic cancer by targeting metastatic tumor cells across multiple cancer types.
TTX Delivery Platform (TTX)
A nanoparticle-based delivery system designed to transport therapeutic RNA and other payloads specifically to tumors and metastatic sites.

Research & Development

Transcode Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 18
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 18
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt
obfuscation
Post-IPO Debt - Transcode Therapeutics Logo
Post-IPO Debt - Transcode Therapeutics
—
obfuscation
— Post-IPO Debt

Investors

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 5 Board Members and Advisors 4 Contacts 13

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

623
-68.46%
 in past month

IT Spend

$163.1KThis year, Transcode Therapeutics is projected to spend $163.1K on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Executive Threat Assessment Logo
Executive Threat Assessment
68
Performance Measurement Logo
Performance Measurement
67

Active Website Tech Count

14Transcode Therapeutics is actively using 14 technologies for its website, according to BuiltWith. These include HSTS, IPv6, and  CommonCrawl Top 5m.
Sub-Organizations
Frequently Asked Questions

Where is Transcode Therapeutics's headquarters? Transcode Therapeutics is located in Newton, Massachusetts, United States.Who invested in Transcode Therapeutics? Transcode Therapeutics has 5 investors including CK Life Sciences International and  CK Life Sciences International.When was the last funding round for Transcode Therapeutics? Transcode Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Debt round.Who are Transcode Therapeutics's competitors? Alternatives and possible competitors to Transcode Therapeutics may include BioAffinity Technologies, Calidi Biotherapeutics, and  Canton Strategic Holdings.How much funding has Transcode Therapeutics raised to date? Transcode Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d46e5f 1)
|